- Home
- GUAC vs EVMN Comparison
GUAC vs EVMN Comparison
Compare GUAC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$14.21
Company Overview
Basic Information| Metric | GUAC | EVMN |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.9M | 405.2M |
| IPO Year | 2026 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GUAC | EVMN |
|---|---|---|
| Price | $9.95 | $14.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $43.88 |
| AVG Volume (30 Days) | 152.5K | ★ 552.3K |
| Earning Date | N/A | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $9.93 | $10.47 |
| 52 Week High | $10.00 | $33.20 |
Technical Indicators
Market Signals| Indicator | GUAC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 56.77 |
| Support Level | N/A | $13.89 |
| Resistance Level | $10.00 | $21.21 |
| Average True Range (ATR) | 0.02 | 0.77 |
| MACD | 0.00 | 0.65 |
| Stochastic Oscillator | 28.57 | 100.00 |
Price Performance
Historical Comparison GUAC
EVMN
About GUAC Berto Acquisition Corp. II Ordinary Shares
Berto Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.